Remegen Co., Ltd.

This study compares two treatments for people with advanced squamous non-small cell lung cancer who have not had prior therapy. Participants will receive either the experimental drug RC148 or the approved drug tislelizumab, both combined with chemotherapy. The goal is to see whic…

This study tests a new drug called RC148 combined with chemotherapy as a first treatment for people with advanced colorectal cancer that cannot be surgically removed. About 80 participants will receive either RC148 plus chemo or the standard bevacizumab plus chemo. The goal is to…

This Phase 3 trial tests whether telitacicept can improve eye muscle symptoms in people with ocular myasthenia gravis, a condition causing droopy eyelids and double vision. About 120 participants aged 12 to 80 will receive either the drug or a placebo for 24 weeks. The study meas…

This phase 3 trial is testing whether a combination of three drugs (disitamab vedotin, trastuzumab, and tislelizumab) works better than standard chemotherapy plus trastuzumab with or without pembrolizumab for people with advanced HER2-high stomach or gastroesophageal junction can…

This study tests a new drug called RC278 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 312 adults aged 18 to 75 with good overall health are being recruite…

This study tests whether a combination of three drugs—disitamab vedotin, pertuzumab, and toripalimab—can shrink or eliminate HER2-positive breast tumors before surgery. About 40 adults with early-stage breast cancer will receive the drugs intravenously for 18 weeks, then have sur…